31 / 88
31
Monday, 19 June 2017
/ Scientific Programme
WFSBP 2017
MON
P-02
POSTER TOUR
13:00–14:30
Congress Hall A 1
Antipsychotics
Chair:
Ofer Agid, Canada
001
Weight gain and gut hormones in patients initiat-
ing clozapine
Marina Garriga, Spain
A. Mallorqui, L. Serrano, C. Oliveira, M. Salamero,
E. Vieta, M. Bernardo, C. García Rizo
002
Cost- efficacy study in patients with psychotic
disorder treated with an atypical depot antipsychotic
Aida Alvarez Pedrero, Spain
B. Bote, C. Marin, R. De Alarcón, C. Lorenzo, J. Matías
003
Toxicity after paliperidone overdose in an Asian
patient: A case report
Maria Marta Jalon Urbina, Spain
L. Gómez de Segura Iriarte, C. M. Rodriguez Mercado, L.
Perez Gomez, L. Garcia Gonzalez, Emeterio Delgado , A.
González Fernández
004
Frequency of NMS diagnosis in calls to a National
Telephone Information Service
Ronald Gurrera, USA
G. Mortillaro, V. Velamoor, S. Caroff
006
DECIDE Study: Effectiveness of shared decision
making in treatment planning at discharge of inpatient
with schizophrenia: 3 years of recruitment, full sample
preliminary analysis
Jose Maria Villagran Moreno, Spain
J. I. Pérez Revuelta, J. M. Mongil San Juan, J. Mestre
Morales, F. González Sáiz
007
DECIDE Study: Influence of share decisions
making strategy on the antipsychotic treatment profile.
Comparison of antipsychotic polytherapy in patients
discharged after acute episode – UHSM, after one year
follow up
Jose Maria Villagran Moreno, Spain
F. González Sáiz, J. I. Pérez Revuelta, J. Mestre Morales,
J. M. Pascual Paño
008
Patient perceived participation in decision-making
on their antipsychotic treatment: Evidence of validity
and reliability of the Spanish version of COMRADE
scale in a sample of schizophrenia spectrum disorder
patients
Jose Ildefonso Pérez Revuelta, Spain
C. Gutiérrez Santaló, G. Vaz Domínguez, J. M. Mongil
San Juan, J. M. Villagran Moreno
009
Satisfaction with antipsychotic as a medication:
The role of the therapeutic alliance and patient per-
ceived participation in decision making in a sample
of schizophrenia spectrum disorder patients
Jose Ildefonso Pérez Revuelta, Spain
M. L. Moreno Sánchez, F. J. Puerto Garrido, J. M. Pascual
Paño, J. M. Villagran Moreno
010
Assessment of the evidences regarding predictive
biomarkers in clozapine-treated patients: A focus on
research methodology
Ferdinando Cerrato, Italy
L. Guizzaro, P. Scudellari, D. De Ronchi, M. Fabrazzo,
A. R. Atti
011
Genetic polymorphisms associated with constipa-
tion and anticholinergic symptoms in clozapine-treated
patients
Anssi Solismaa, Finland
O. Kampman, L.-P. Lyytikäinen, N. Seppälä, M. Viikki,
N. Mononen, T. Lehtimäki, E. Leinonen
013
How to combine risperidone with low-potency
First Generation Antipsychotics (FGA): Decision making
based on pharmacokinetic considerations
Georgios Schoretsanitis, Switzerland
E. Haen, B. Stegmann, C. Hiemke, G. Gründer,
M. Paulzen
014
A case presentation of the reintroduction of
clozapine in a patient who developed neutropenia:
Taking risks for a greater benefit
Jose Maria Villagran Moreno, Spain
J. I. Pérez Revuelta, C. Rodríguez Gómez
015
Detoxifying enzymes are increased in aripipra-
zole-treated PC12 cells
Miyuki Ota, Japan
G. Takami, Y. Kaneko, H. Nagasaki, Y. Kodani,
A. Nakashima, K. Mori, A. Ota
016
Control of symptoms and safety with the adminis-
tration of paliperidone palmitate 3-month formulation
José Ángel Alcalá Partera, Spain
A. B. Rico del Viejo, J. L. Prados Ojeda
018
Efficacy of Lurasidone in schizophrenia:
A systematic review and meta-analysis of RCTs
with active comparators
Tadashi Nosaka, Japan
K. Hagi, K. Hagi, A. Pikalov, A. Loebel, J. Kane
019
Safety of Lurasidone in schizophrenia: A systematic
review and meta-analysis of RCTs with active comparators
Katsuhiko Hagi, Japan
T. Nosaka, A. Pikalov, A. Loebel, J. Kane